WorldChinaJapanIndiaSouth KoreaIndonesiaTaiwanThailandU.S.East AsiaChinaHong KongMacaoTaiwanMongoliaJapanSouth KoreaNorth KoreaSoutheast AsiaIndonesiaThailandMalaysiaSingaporePhilippinesVietnamMyanmarCambodiaLaosBruneiEast TimorSouth AsiaIndiaPakistanAfghanistanBangladeshSri LankaNepalBhutanMaldivesCentral AsiaKazakhstanUzbekistanTurkmenistanTajikistanKyrgyzstanOceaniaAustraliaNew ZealandPapua New GuineaPacific IslandsRest of the WorldMiddle EastRussia & CaucasusNorth AmericaLatin AmericaEuropeAfricaTrendingIran tensionsInflationTrump administrationArtificial intelligenceElectric vehiclesSupply ChainTaiwan tensionsBank of JapanImmigrationESGExplainerBusinessBusinessSemiconductorsAutomobilesEnergyTransportationRetailTravel & LeisureMedia & EntertainmentFood & BeverageFinanceElectronicsStartupsBusiness dealsMarketsMarketsEquitiesCurrenciesBondsCommoditiesPropertyIPOWealth ManagementTechTech#techAsiaChina techStartupsCryptocurrenciesDealStreetAsiaPoliticsPoliticsChinaJapanIndiaSouth KoreaIndonesiaTaiwanThailandU.S.East AsiaChinaHong KongMacaoTaiwanMongoliaJapanSouth KoreaNorth KoreaSoutheast AsiaIndonesiaThailandMalaysiaSingaporePhilippinesVietnamMyanmarCambodiaLaosBruneiEast TimorSouth AsiaIndiaPakistanAfghanistanBangladeshSri LankaNepalBhutanMaldivesCentral AsiaKazakhstanUzbekistanTurkmenistanTajikistanKyrgyzstanOceaniaAustraliaNew ZealandPapua New GuineaPacific IslandsRest of the WorldMiddle EastRussia & CaucasusNorth AmericaLatin AmericaEuropeAfricaEconomyEconomyChinaJapanIndiaSouth KoreaIndonesiaTaiwanThailandU.S.East AsiaChinaHong KongMacaoTaiwanMongoliaJapanSouth KoreaNorth KoreaSoutheast AsiaIndonesiaThailandMalaysiaSingaporePhilippinesVietnamMyanmarCambodiaLaosBruneiEast TimorSouth AsiaIndiaPakistanAfghanistanBangladeshSri LankaNepalBhutanMaldivesCentral AsiaKazakhstanUzbekistanTurkmenistanTajikistanKyrgyzstanOceaniaAustraliaNew ZealandPapua New GuineaPacific IslandsRest of the WorldMiddle EastRussia & CaucasusNorth AmericaLatin AmericaEuropeAfricaFeaturesTrading AsiaASEAN MoneyTech AsiaBusiness AsiaChina Up ClosePolicy AsiaBig in AsiaDatawatchInfographicsOpinionOpinionEditor-in-Chief's PicksThe Nikkei ViewLife & ArtsLife & ArtsLifeArtsMy Personal HistoryTea LeavesEat & DrinkDestinationsBooksObituariesWatch & ListenPodcastsVideoPhotosPharmaceuticalsCollaboration underlines surge in cross-border biotech licensing agreementsUnder a deal, Takeda will have access to Insilico Medicine's generative AI platform on drug development. (Source photos by Takeda and Insilico Medicine websites) LORRETTA CHENJuly 2, 2026 12:27 JSTHONG KONG -- Japanese pharmaceutical giant Takeda has reached a deal with Hong Kong-based Insilico Medicine to use the biotechnology company's artificial intelligence platform to identify potential new drugs.Read NextLatest on PharmaceuticalsSponsored ContentAbout Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.